The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
Subscribe To Our Newsletter & Stay Updated
